Peripheral T-Cell Lymphomas–Not Otherwise Specified: A Shrinking Entity?

Presented by:
Steven M. Horwitz
Search for other papers by Steven M. Horwitz in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

Peripheral T-cell lymphomas–not otherwise specified (PTCL-NOS) is a broad category of biologically and clinically heterogeneous diseases, which likely does not have a single treatment paradigm. Understanding of subtype-specific approaches is leading to more individualized therapy. There are also therapeutic vulnerabilities to target, such as CD30, JAK/STAT pathway, and epigenetic modifiers, that may cross different histologic subtypes. As new therapies evolve, however, it is important to understand in which situations current standard treatments work, because some of these treatments, such as combination chemotherapy, are potentially curative for a subset of patients. For certain populations, adding to these chemotherapy backbones will produce the best results. For other populations, entirely new approaches may be appropriate. Future treatment advances will, in part, be made by enriching populations based on their likelihood of response to specific therapies and utilizing biomarker-driven or biomarker-informed strategies.

Disclosures: Dr. Horwitz had disclosed that he has received consulting fees from Astex Pharmaceuticals; Celgene Corporation; Janssen Pharmaceutica Products, LP; Kura Oncology, Inc.; Kyowa Hakko Kirin Co., Ltd.; ADCT; C4 Therapeutics; Curio; Myeloid Therapeutics; Verastem; Seattle Genetics, Inc.; and Takeda Pharmaceuticals North America, Inc. He has also received grant/research support from Celgene Corporation; Daiichi-Sankyo Co.; Forty Seven, Inc.; ADCT; Aileron; Corvus; Trillium; Verastem; Portola Pharmaceuticals, Inc.; and Seattle Genetics, Inc.

Correspondence: Steven M. Horwitz, MD, Memorial Sloan Kettering Cancer Center, Department of Hematology, 1275 York Avenue, New York, NY 10021. Email: horwitzs@mskcc.org
  • Collapse
  • Expand
  • 1.

    Schmitz N, Trümper L, Ziepert M, et al.. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:34183425.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    d'Amore F, Relander T, Lauritzsen GF, et al.. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:30933099.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Horwitz S, O'Connor OA, Pro B, et al.. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019;393:229240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Ghione P, Ozkaya N, Faruque P, et al.. Romidepsin activity in T follicular helper (TFH)-phenotype PTCL versus non TFH treated on the same clinical trials [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 7509.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Odejide O, Weigert O, Lane AA, et al.. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014;123:12931296.

  • 6.

    Dupuis J, Morschhauser F, Ghesquières H, et al.. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Lancet Haematol 2015;2:e160165.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Horwitz SM, Koch R, Porcu P, et al.. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 2018;131:888898.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Moskowitz AJ, Ghione P, Jacobsen ED, et al.. Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma [abstract]. Blood 2019;134(Suppl 1):Abstract 4019.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Ishikawa C, Senba M, Mori N. Anti-adult T-cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor. Int J Oncol 2018;53:16811690.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Witzig TE, Sokol L, Foss FM, et al.. Proof of concept for tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL): preliminary results from an open-label, phase 2 study [abstract]. Blood 2019;134(Suppl 1):Abstract 468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 925 292 11
PDF Downloads 477 34 6
EPUB Downloads 0 0 0